HYSORPTASE®

Our HYSORPTASE® is a recombinant human hyaluronidase (rHuPH20) synthesized in vitro using mammalian cells. It locally degrades subcutaneous hyaluronic acid (HA), temporarily removing barriers to fluid flow. In this way, the subcutaneous dosage volume limitation of 2 mL can be broken through, enabling the safe and efficient absorption of up to 1 L of drug volume through the subcutaneous route.

Developing co-formulations with HYSORPTASE® and biologics, small molecule drugs, etc., can allow these drugs to overcome the subcutaneous dosage volume limitation, facilitating rapid, convenient, and safe high-dose administration. This enhances patient experience, brings benefits to the higher efficiency of healthcare systems, and boosts the competitiveness of manufacturers.

In global markets, seven subcutaneous products using hyaluronidase co-formulation technology have received regulatory approvals.

HYSORPTASE® has been applied in hundreds of clinical cases.

HYSORPTASE® co-formulations with multiple partnered antibodies are at various stages of clinical research.

Bao Pharma develops and produces recombinant human hyaluronidase Hysorptase® in accordance with the quality management requirements for recombinant protein drugs. The manufacturing process meets current GMP standards and the production scale meets commercialization needs.

With Hysorptase® we are able to break through the limitations of conventional subcutaneous delivery volume, providing convenient subcutaneous options for patients in hospitals or at home.

Hysorptase® has completed clinical validation for effectively promoting the subcutaneous dispersion of drugs. Moreover, there are multiple co-formulation collaboration projects at various stages of development.